Global Drug Modeling Software Market, By Components (Software, and Services), Operating System (Windows, Linux, Mac Os, and Others), Deployment Mode (Cloud Based, Hybrid-Based, and On-Premises), Enterprise Size (Large Enterprise Size, Small & Medium Enterprise Size), Application (Graphical Molecular Modeling, Gene Sequence Analysis, Protein Modeling, Modeling Crystal Structures, Cheminformatics, High Throughput Virtual Screening, Gas & Solution Phase Reaction, Medical Imaging, and Others), Purchase Model (Subscription Based, and One- Time License), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organization, Research Institutes, Regulatory Authorities, and Others) - Industry Trends and Forecast to 2030.
Drug Modeling Software Market Analysis and Insights
The global drug modeling software market is expected to grow in the forecast period due to the rising drug discovery and development activities and rising demand for novel therapies. The market is also influenced by precision medicine and intervention of AI in drug modelling However, the global drug modeling software market is expected to be hampered by a lack of quality data base and the high cost of manufacturing drug modelling software.
Data Bridge Market Research analyses that the drug modeling software market is expected to grow at a CAGR of 9.2% during the forecast period of 2023 to 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in Million, Pricing in USD
|
|
Segments Covered
|
Components (Software, and Services), Operating System (Windows, Linux, Mac Os, and Others), Deployment Mode (Cloud Based, Hybrid-Based, and On-Premises), Enterprise Size (Large Enterprise Size, Small & Medium Enterprise Size), Application (Graphical Molecular Modeling, Gene Sequence Analysis, Protein Modeling, Modeling Crystal Structures, Cheminformatics, High Throughput Virtual Screening, Gas & Solution Phase Reaction, Medical Imaging, and Others), Purchase Model (Subscription Based, and One- Time License), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organization, Research Institutes, Regulatory Authorities, and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium, Poland, Sweden, Denmark, Finland, Norway, and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, Vietnam, Taiwan, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Oman, Bahrain, Kuwait, Qatar, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Dotmatics, BC Platforms, InSilicoTrials Technologies., VeriSIM Life., Atomwise Inc., Certara, USA., GENECODE, Cresset., and Nanome Inc. SIMULATIONS PLUS., Dassault Systèmes, Scripps Research, XtalPi Inc., Xybion, ArgusLab, Schrödinger, Inc. among others.
|
Market Definition
The drug modeling software refers to the industry segment that provides software tools and solutions for computational drug design and discovery. Drug modeling software offers a range of functionalities, including molecular docking, virtual screening, structure-based drug design, ligand-based drug design, molecular dynamics simulations, and pharmacophore modeling. These tools assist in predicting the efficacy, safety, and pharmacokinetic properties of drug candidates, optimizing lead compounds, and accelerating the drug discovery process.
Global Drug Modeling Software Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising drug discovery and development activities
Drug development covers all the activities undertaken to transform the compound obtained during drug discovery into a product that is approved for launch into the market by regulatory agencies.
The process of creating a new drug product can be broadly divided into three main phases:
- Drug discovery – entailing the conceptualization of the therapeutic into a molecule with known pharmacologic effects.
- Drug development – covering the steps taken to convert the molecule above into an approved and registered drug product.
- Commercialization – This includes all the steps taken to convert the product into an approved therapeutic, launch it into the market, and generate sales.
The drug discovery process technically starts with choice of a disease area and a definition of the therapeutic need that should be addressed. Once this is done, the process proceeds to identification of the physiological mechanisms that need to be targeted, and ideally, identification of a specific molecular ‘drug target’. During this phase, effort is focused on identifying a lead chemical structure, designing, testing, and fine-tuning it, and ensuring that it meets all the criteria required for development into a drug product.
Drug modeling software plays a crucial role in the pharmaceutical industry by providing computational tools and algorithms that aid in the design, development, and optimization of new drugs. This technology has gained prominence due to its ability to accelerate the drug discovery process, reduce costs, and enhance the success rates of drug candidates
- Rising demand for novel therapies
Drug modelling software adoption is intimately related to the expanding demand for novel therapeutics in the pharmaceutical sector. Drug modelling software is essential for enhancing drug prospects, speeding up the drug research and development process, and increasing the success rates of novel medicines.
The World Health Organization estimates that chronic diseases account for approximately 71% of all deaths worldwide. The increasing prevalence of these conditions drives the demand for novel therapies that can provide better disease management, improved outcomes, and enhanced quality of life for patients
The increasing need for novel therapeutics in drug modeling software is demonstrated by these instances. Drug modelling software is being used more frequently as a result of its potential to produce targeted therapeutics, accelerate the drug development process, improve drug candidates, facilitate virtual screening, and enhance combination medicines. Therefore, rising demand for novel therapies is expected to drive the market growth
Opportunity
- Cloud computing and big data analytics in drug modelling
Organizations are using cloud computing and big data analytics technology to handle immense volumes of data with better automation, generate data driven insights, mimic human intelligence and much more. The wide range of benefits offered by Cloud computing and big data analytics is increasing its adoption in almost every business. Today, many leading pharma companies are leveraging Cloud computing and big data analytics technology to enhance their processes of manufacturing, drug research, and development.
In order to simulate drugs, massive and varied datasets can be mined using big data analytics approaches. Researchers can use modern analytics algorithms, such machine learning and data mining, to analyse and interpret complicated drug-related data by utilizing cloud computing capabilities. These methods enable target identification, lead optimization, and drug repurposing by spotting patterns, correlations, and trends.
Therefore cloud computing and big data analytics in drug modelling are expected to create an opportunity for the growth of the market.
Restraint/Challenge
- Lack of procedure for multi drug effect assessment
The effects of multiple drugs, also known as polypharmacy, in drug modeling can be challenging due to the complexity of interactions between multiple compounds and their targets.
Here are some factors contributing to this lack of standardized procedures:
- Data Availability and Integration
- Complexity of Drug Interactions
- Combinatorial Space
- Lack of Standardized Experimental Designs
- Regulatory Considerations
The rise of multi drug resistant and extensively drug resistant bacteria around the world, poses a great threat to human health and defines a need to develop new, effective and inexpensive anti-bacteria agents. The mystery of chemicals and chemistry is how structure or substructures are related to chemical behavior and activity.
Efforts to collect and integrate comprehensive data on drug interactions, standardize experimental protocols, and develop advanced modeling techniques specifically tailored for multi-drug assessments are necessary. Lack of procedure for multi drug effect assessment is expected to act as a significant challenge in the growth of the market.
Recent Developments
- In May 2023, Cresset announced the latest release of molecular modeling platform that delivers improved efficiencies for small molecule discovery therefore Flare V7. This helps the organisation developing more revenue.
- In December 2022, Pharma Celera, and Enamine, announced a partnership to jointly provide an efficient solution for hit finding therefore ultra-large chemical libraries are observed as one of the key paradigms to access an unexplored chemical space. The partnership helps the organisation in developing more revenue by modifying its portfolio.
Global Drug Modeling Software Market Segmentation
The global drug modeling software market is segmented into seven notable segment namely, component, operating system, deployment mode, enterprise size, application, purchasing model, end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Components
- Software
- Services
Based on components, global drug modeling software market is segmented into software and services.
Operating System
- Windows
- Linux
- Mac Os
- Others
Based on operating system, global drug modeling software market is segmented into windows, linux, mac os, and others.
Deployment Mode
- Cloud Based
- Hybrid-Based
- On-Premises
Based on deployment mode, global drug modeling software market is segmented into cloud based, hybrid-based, and on-premises.
Enterprise Size
- Large Enterprise Size
- Small & Medium Enterprise Size
Based on enterprise size, global drug modeling software market is segmented into large enterprise size, small and medium enterprise size.
Application
- Graphical Molecular Modeling
- Gene Sequence Analysis
- Protein Modeling
- Modeling Crystal Structures
- Cheminformatics
- High Throughput Virtual Screening
- Gas & Solution Phase Reaction
- Medical Imaging
- Others
Based on the application, global drug modeling software market is segmented into graphical molecular modeling, gene sequence analysis, protein modeling, modeling crystal structures, cheminformatics, high throughput virtual screening, gas & solution phase reaction, medical imaging, and others.
Purchasing Model
- Subscription Based
- One-Time License
Based on the purchasing model, global drug modeling software market is segmented into subscription based, and one- time license.
End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organization
- Research Institutes
- Regulatory Authorities
- Others
Based on end user, global drug modeling software market is segmented into pharmaceutical & biotechnology companies, contract research organization, research institutes, regulatory authorities, and others.
Global Drug Modeling Software Market Regional Analysis/Insights
The drug modeling software market is analyzed, and market size insights and trends are provided based on components, operating system, deployment mode, enterprise size, application, purchasing model, end user.
The countries covered in this market report are the U.S., Canada, and Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium, Poland, Sweden, Denmark, Finland, Norway, and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, Vietnam, Taiwan, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Oman, Bahrain, Kuwait, Qatar, and Rest of Middle East and Africa.
North America is expected to dominate the global drug modeling software market due to the rising drug discovery and development activities and rising demand for novel therapies. The U.S. is expected to dominate the market due to precision medicine and intervention of artificial intelligence in drug modelling. Germany is expected to dominate the Europe region due to the increasing cloud computing and big data analytics in drug modelling. The demand in this region is projected to be driven by increasing adoption of modeling tools in drug discovery. China is expected to dominate the Asia-Pacific region due to rise in technological advancement in the country.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Drug Modeling software Market Share Analysis
The drug modeling software market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the market.
Some of the key players operating in the global drug modeling software market are Dotmatics, BC Platforms, InSilicoTrials Technologies., VeriSIM Life., Atomwise Inc., Certara, USA., GENECODE, Cresset., and Nanome Inc. SIMULATIONS PLUS., Dassault Systèmes, Scripps Research, XtalPi Inc., Xybion, ArgusLab, Schrödinger, Inc. among others.
SKU-